CX-2051 / CytomX - LARVOL DELTA

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) (GlobeNewswire) - P1 | N=124 | NCT06265688 | Sponsor: CytomX Therapeutics | "CytomX Therapeutics, Inc...announced positive interim Phase 1 data for its EpCAM PROBODY ADC candidate, CX-2051, in advanced, late-line CRC....Overall response rate (ORR): 28% of patients (5/18) achieved confirmed partial RECIST v. 1.1 responses. Overall response rates for currently approved therapies in 3rd line or later CRC are in the low to mid-single digit percentages. At the 10 mg/kg dose, 3 of 7 evaluable patients (43%) achieved confirmed partial responses. The Disease Control Rate was 94% across the three dose groups (17/18)....Dose expansions have been initiated at doses of 7.2 mg/kg, 8.6 mg/kg and 10 mg/kg Q3W. A total of 20 patients are expected to be enrolled at each dose level to inform the selection of recommended phase 2 dose."

P1 data • Trial status • Colorectal Cancer

CX-2051 Anticipated Milestones (GlobeNewswire) - "CX-2051 Monotherapy for Advanced Late-Line CRC: Additional Phase 1 data update by Q1 2026; Planning Phase 2 study initiation in 1H 2026. CX-2051 CRC Combinations: Potential to initiate CX-2051 combination studies in earlier lines of CRC in 2026. CX-2051 Pan-tumor Potential: Evaluate non-CRC, EpCAM-expressing tumor indications for potential Phase 1b study initiation in 2026."

New P1 trial • New P2 trial • New trial • P1 data • Colorectal Cancer

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Pipeline Program Updates: (i) CX-2051 (EpCAM PROBODY Topo-1 ADC)...The CX-2051 Phase 1 study is ongoing and is evaluating the seventh dose level. Initial Phase 1a data in CRC are expected to be presented in the first half of 2025....; (ii) CX-801 (PROBODY Interferon-alpha 2b):...The Phase 1 study is currently in the fourth monotherapy dose escalation cohort where the dose of CX-801 exceeds the approved dose of the unmasked peginterferon alfa-2b (SYLATRON). Initial Phase 1a translational and biomarker data in advanced melanoma is expected in the second half of 2025."

P1 data • Trial status • Melanoma • Solid Tumor

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update (GlobeNewswire) - "Clinical Program Updates and 2025 Milestones: CX-2051 (EpCAM PROBODY ADC):...The Phase 1 study of CX-2051 was initiated in April of 2024 and is focused in advanced metastatic CRC, one of many tumor types in which high expression of EpCAM has been documented....The CX-2051 study is currently in the sixth dose escalation cohort with patient enrollment to-date focused in advanced CRC patients who have generally received three or more prior lines of systemic therapy in the metastatic setting....In Phase 1 dose escalation to date, CX-2051 has demonstrated a favorable tolerability profile at dose levels predicted to be biologically active based on preclinical data. Initial Phase 1a data are expected in the first half 2025."

P1 data • Trial status • Colorectal Cancer

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Third Quarter Business Highlights and Recent Developments:...(i) CX-2051:...The Phase 1 study of CX-2051 was initiated in Q2 2024 and is currently focused in metastatic colorectal cancer....The study is currently enrolling the fifth dose escalation cohort with favorable safety and tolerability having been observed to date. Initial Phase 1a data are expected in the first half 2025...; (ii) CX-801:...Phase 1 dose escalation is ongoing with a primary focus in melanoma. The study will evaluate safety and initial clinical activity for CX-801 monotherapy and for CX-801 in combination with KEYTRUDA. Initial Phase 1a data are expected in the second half of 2025."

P1 data • Trial status • Colorectal Cancer • Melanoma

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Priorities and Key Milestones: (i) CX-904 (EGFRxCD3): Continued Phase 1a dose escalation in PDAC, HNSCC and NSCLC focused on the selection of recommended Phase 1b dose(s); A CX-904 Phase 1 program update is expected by the end of 2024, including a potential decision to initiate Phase 1b expansion cohorts in specific EGFR positive tumor types; (ii) CX-2051 (EpCAM): Continued Phase 1 dose escalation in solid tumors, primarily CRC; Initial Phase 1a data expected in the first half of 2025; (iii) CX-801 (IFNα2b): Continued Phase 1 dose escalation progress in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma. Initial Phase 1a data expected in the second half of 2025."

P1 data • Trial status • Colorectal Cancer • Melanoma • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma • Renal Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) - "In April 2024, the first patient was dosed as part of the Phase 1 dose escalation of CX-2051 in patients with solid tumors generally known to express EpCAM, including CRC. The first dose cohort in the CX-2051 Phase 1 study has been cleared and dose escalation continues. The Phase 1 dose escalation study is following a Bayesian Optimal Interval (BOIN) design....Initial data for CX-2051 is expected in the first half of 2025."

P1 data • Trial status • Colorectal Cancer

CTMX-2051-101: First In Human Study of CX-2051 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: CytomX Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors (GlobeNewswire) - "CytomX Therapeutics...announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors....The cytotoxic payload utilized in CX-2051 is a derivative of camptothecin, a topoisomerase-1 inhibitor, a class of drug that has shown potent clinical anti-cancer activity and demonstrated significant clinical benefit as an approved ADC in multiple cancers. The CX-2051 Phase 1 dose escalation is designed to efficiently test the safety and preliminary anti-tumor activity of CX-2051, to provide initial clinical proof of concept to inform a potential decision to move into dose expansions in 2025."

Trial status • Solid Tumor

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update (GlobeNewswire) - "CX-2051 (EpCAM): Initiation of Phase 1 dose escalation in solid tumors with known EpCAM expression, including locally advanced/metastatic colorectal cancer as a priority indication, is expected in the first half of 2024."

Trial status • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

First In Human Study of CX-2051 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=124 | Not yet recruiting | Sponsor: CytomX Therapeutics

Metastases • New P1 trial • Oncology • Solid Tumor

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b (GlobeNewswire) - "CytomX Therapeutics...announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) applications for the conditionally activated Probody therapeutics CX-2051, an EpCAM-directed ADC, and CX-801, a dually-masked version of interferon-alpha 2b. CX-2051 has been cleared for the initiation of Phase 1 dose escalation in solid tumors with known EpCAM expression and CX-801 has been cleared for the initiation of Phase 1 dose escalation in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma. Both programs are expected to start Phase 1 studies in the first half of 2024."

IND • New P1 trial • Melanoma • Renal Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones (GlobeNewswire) - "CX-2051 (EpCAM): Initiation of Phase 1 dose escalation in solid tumors with known EpCAM expression including metastatic colorectal cancer as one priority indication is expected in the first half of 2024; CX-801 (IFNα2b): Initiation of Phase 1 dose escalation in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma is expected in the first half of 2024."

New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) - "CX-904, T-cell-engaging bispecific (TCB) targeted to EGFRxCD3, Phase 1 dose escalation data anticipated in the first half of 2024...Backfilling of certain dose escalation cohorts is being initiated during Q4 2023. Initial Phase 1a data for CX-904 is anticipated in the first half of 2024. A decision to initiate Phase 1b expansion cohorts in certain EGFR positive tumor types is anticipated in 2024....The IND for CX-2051 is expected to be filed by the end of 2023. CX-2051 Phase 1 dose escalation in solid tumors is anticipated in 2024, with metastatic colorectal cancer as a priority indication."

IND • New P1 trial • P1 data • Trial status • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Leveraging Conditional Activation to Localize Antibody Drug Conjugates to the Tumor (ADC-USA 2023) - "Describing CytomX Therapeutics, which is a clinical-stage company developing tumor-localized oncology therapeutics; Reviewing CX-2051, which is a conditionally activated antibody drug conjugate targeted against EpCAM; Outlining how the therapeutic index can be widened by optimally pairing the target, payload, and indication of an ADC"

Oncology

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference (GlobeNewswire) - "CytomX Therapeutics...announced that the Company presented data characterizing the preclinical profile of its EpCAM-targeting ADC, CX-2051, at the World ADC conference taking place October 16-19, 2023....Preclinical data demonstrate a favorable predicted therapeutic index and efficacy across multiple EpCAM-expressing tumors, including colorectal cancer (CRC). CX-2051 IND filing expected by year-end 2023...'We aim to launch Phase 1 dose escalation for CX-2051 in solid tumors in 2024, with an initial focus in metastatic colorectal cancer as a priority indication'."

IND • New P1 trial • Preclinical • Colorectal Cancer

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) - "Priorities for 2023: (i) File 2 New INDs (wholly-owned): CX-801 (IFNa2b) and CX-2051 (EpCAM) INDs projected in the fourth quarter of 2023."

IND • Oncology

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) - "IND filings anticipated in 2H 2023 for Wholly Owned CX-801, Interferon (IFN) alpha-2b, and CX-2051, EpCAM-directed ADC."

IND • Oncology • Solid Tumor

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities (GlobeNewswire) - "2023 KEY MILESTONES AND OUTLOOK - CX-904 (EGFRxCD3): Continue patient enrollment and dose escalation in ongoing Phase 1 study; File 2 New INDs: CX-801 (IFNa2b) and CX-2051 (EpCAM) projected in 2H 2023."

IND • Trial status • Oncology • Solid Tumor

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) - "Third Quarter Business Highlights and Recent Developments:...CytomX’s strategy with CX-2051 is to match target expression and sensitivity to the camptothecin payload with prioritized indications. CX-2051 data presented at World ADC demonstrated strong preclinical activity and a favorable predicted therapeutic index."

Preclinical • Oncology

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) - "Priorities for 2022/2023: (i) Submit INDs for CX-801 and CX-2051 in the second half of 2023."

IND • Oncology

CytomX Therapeutics Provides Strategic Update (GlobeNewswire) - "CX-801 has broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. An IND submission is planned in 2023. EpCAM-directed ADC program - CX-2051 is a wholly-owned conditionally activated ADC directed toward EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. An IND submission is planned in 2023."

IND • Oncology • Solid Tumor